@queercme's testosterone hair loss claims, fact-checked

What did @queercme actually say?

A trans physician laid out a practical framework for understanding androgenic alopecia in people taking testosterone for gender-affirming care. The core argument: hair loss on testosterone is "semi-permanent, not permanent" until a follicle has been gone for 12 months, which creates a window for intervention. Their preferred tool is low-dose oral minoxidil at 2.5 to 5 mg daily, which they favor over 5-alpha reductase inhibitors because those drugs can blunt testosterone's effects elsewhere in the body. They also flagged that topical minoxidil is toxic to pets and hard to apply effectively through thick hair.

They were careful to say no intervention stops hair loss entirely. "They slow it down gradually over time," they said, which is a more honest framing than a lot of hair-loss content out there. They also addressed the genetics, noting that because many transmasculine people carry two X chromosomes, the inherited risk can come from either parent, not just the maternal line.

Does the science back this up?

Mostly, yes, with one significant asterisk on the 12-month follicle claim. The genetics framing is solid. The minoxidil preference is well-supported. The 5-alpha reductase inhibitor trade-off is real and clinically relevant for this population.

On oral minoxidil: a 2022 randomized controlled trial by Randolph and Tosti in the Journal of the American Academy of Dermatology confirmed low-dose oral minoxidil (1.25 to 5 mg) is effective and generally well-tolerated for androgenic alopecia, with side effects including hypertrichosis and fluid retention. A 2021 review by Vano-Galvan et al. in Dermatology and Therapy similarly supported its use. The topical toxicity claim for pets is accurate. The ASPCA lists minoxidil as a known feline and canine toxin, with cardiac effects reported in cats specifically.

The genetics point about X-linked inheritance being incomplete for people with two X chromosomes is accurate. Research confirms androgen receptor gene variants are not the only factor. Autosomal genes also contribute meaningfully to androgenic alopecia risk.

What did they get wrong (or right)?

The 12-month follicle window is where this gets complicated. The creator states that when "a hair follicle falls out, we have 12 months to revive it before it's permanently unavailable." This is an oversimplification that could give viewers false confidence in the timeline.

Follicle miniaturization in androgenic alopecia is a gradual process, not a binary alive-or-dead event triggered by a single shed. Dermatology literature, including work by Whiting in the Journal of Investigative Dermatology Symposium Proceedings (1998), shows follicles cycle through progressive miniaturization over years. The 12-month figure lacks a clear citation basis and is not a standard clinical threshold. Follicles can remain partially viable well beyond that point, and some recover even after longer periods with treatment. The claim is directionally useful but presented with more precision than the evidence supports.

What they got right: the pet toxicity warning is underreported and genuinely useful. The honest framing that no treatment fully stops genetic hair loss is refreshing compared to the oversold content that floods this space.

What should you actually know?

If you're taking testosterone and concerned about hair loss, the practical takeaway is that acting early is better than waiting, but the 12-month clock is not a hard deadline backed by robust clinical data. Androgenic alopecia is a chronic, progressive condition. Treatments like minoxidil work by prolonging the anagen phase of hair growth, and their effectiveness is higher when follicles are still active, but "still active" is not reliably determined by time elapsed since shedding alone.

The 5-alpha reductase inhibitor trade-off is a real clinical consideration. Finasteride and dutasteride work by reducing DHT conversion, which is the same mechanism that drives virilization. Using them in someone seeking masculinizing effects is a legitimate trade-off conversation, not a blanket contraindication. Some transmasculine patients do use them, typically topically, to minimize systemic DHT suppression. That nuance was present in the video but could have been clearer.

• Biotin supplements, mentioned briefly in the video, have weak evidence for hair loss in people without a biotin deficiency. A 2017 review by Patel et al. in Skin Appendage Disorders found most supporting studies were in deficient populations only.
• Derma rolling and PRP have some supporting evidence but data quality is inconsistent. PRP studies are often small and not placebo-controlled.
• Laser light therapy (low-level laser therapy) has FDA clearance for hair loss but effect sizes in trials are modest.

Bottom line

This is one of the more clinically grounded hair-loss videos you'll find on TikTok, particularly for a transmasculine audience. The 12-month follicle claim is the weakest link and should not be taken as a precise clinical deadline. The oral minoxidil recommendation reflects current dermatology practice, and the honesty about long-term limitations is worth noting. Talk to a provider before starting any hair-loss treatment, especially if you're also managing testosterone therapy.